Role of zoledronic acid in the prevention and treatment of osteoporosis

31Citations
Citations of this article
87Readers
Mendeley users who have this article in their library.

Abstract

Taken once a year, intravenous zoledronic acid (Zol) (Reclast® or Aclasta®) is a third-generation nitrogen-containing bisphosphonate that is effective compared with placebo in reducing the risk of fractures in patients with postmenopausal osteoporosis and recent low- trauma hip fracture. In glucocorticoid-induced osteoporosis, there is no significant difference between Zol and risedronate for new fractures. Improvements in bone mineral density and early reduction of bone remodeling markers are observed in postmenopausal osteoporosis, recent low-trauma hip fracture, and glucocorticoid-induced osteoporosis. Given that Zol is generally well tolerated and very convenient, it is an interesting therapeutic option for aging patients who take multiple oral drugs, who have adherence or gastrointestinal tolerance issues, and who have an indication for oral bisphosphonates. Zol is not recommended for patients with severe renal impairment. Vitamin D deficiency should be corrected before the administration of Zol. © 2011 Räkel et al, publisher and licensee Dove Medical Press Ltd.

Author supplied keywords

Cite

CITATION STYLE

APA

Räkel, A., Boucher, A., & Ste-Marie, L. G. (2011). Role of zoledronic acid in the prevention and treatment of osteoporosis. Clinical Interventions in Aging. Dove Medical Press Ltd. https://doi.org/10.2147/CIA.S7282

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free